Company intelligence / Profile preview
Recludix Pharma
- Ownership
- Private
- Employees
- ~55
- Development stage
- Preclinical
Overview
Recludix has demonstrated preclinical proof-of-concept for its oral small molecule inhibitors targeting the SH2 domains of STAT6 and STAT3. The lead program REX‑8756 (STAT6 inhibitor) shows high potency/selectivity in biochemical/cellular assays and efficacy in murine asthma models. REX‑7117 (STAT3 inhibitor) has shown strong efficacy in vivo versus JAK/TYK2 inhibition for inflammatory arthritis models. No human clinical data reported as of May 2025.
- Therapeutic areas
- GastroenterologyPulmonologyImmunologyDermatologyNeurology
- Modalities
- Small molecules (oral inhibitors)
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Recludix Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Recludix Pharma.